KRAS and non-small cell lung carcinoma: Renaud S et al. [42] analyzed 1190 KRAS mutated stage IV NSCLC patients receiving first-line platinum-based chemotherapy and found that compared with pemetrexed and vinorelbine group, the paclitaxel group had the highest ORR (P < 0.001) and significantly improved TTP (P < 0.001).